Yıl: 2021 Cilt: 5 Sayı: 3 Sayfa Aralığı: 279 - 284 Metin Dili: İngilizce DOI: 10.25048/tudod.959022 İndeks Tarihi: 04-01-2022

COVID-19 and Diabetes Mellitus: Are there any Differences in Outcomes with Anti-Diabetic Drugs?

Öz:
Aim: This study aims to analyze the effect of diabetes and diabetes drugs on the outcome of COVID-19 patients. Material and Methods: All the patients with diabetes hospitalized for COVID-19 between March 15, 2020 and June 15, 2020 at Istanbul University Faculty of Medicine were screened. Outcomes of the patients were compared with patients without diabetes. Results: Among six hundred fourteen patients (59.8% male, n=367) there were 151 patients with diabetes (24.5%). Patients with diabetes were hospitalized longer than patients without (12.1±10.3 vs. 10.2±7.3, p=0.037 in days), had higher intensive care unit (ICU) hospitalization rate (20.5% (n=31) vs. 12.0% (n=56), p=0.016, OR:1.8 (1.1-2.9)) and mortality rate (15.8% (n=24) vs. 7.7% (n=36, p=0.007), OR:2.1(1.2-3.8)). There was no difference in admission to ICU between patients who use metformin, basal insulin or bolus insulin regarding admission to ICU compared to patients who don’t (p= 0.32, p=0.22 and p=0.64, respectively). No patient on sodium-glucose co-transporter-2 treatment was treated in ICU. Death rate didn’t differ between patients regarding their treatment modalities. Conclusion: Patients with diabetes had worse outcomes than non-diabetic patients, and according to our findings and no anti-diabetic drug has a beneficial or harmful effect.
Anahtar Kelime:

Covid-19 ve Diyabet: Antidiyabetik İlaçlar ile Sonlanımlarda Fark Var mı?

Öz:
Amaç: Bu çalışma, diyabet ve diyabet ilaçlarının COVID-19 hastalarının sonuçları üzerindeki etkisini analiz etmeyi amaçlamaktadır. Gereç ve Yöntemler: 15 Mart 2020-15 Haziran 2020 tarihleri arasında İstanbul Üniversitesi İstanbul Tıp Fakültesi'nde COVID-19 nedeniyle hastaneye yatırılan tüm diyabet hastaları tarandı. Hastaların sonuçları diyabeti olmayan hastalarla karşılaştırıldı. Bulgular: Altı yüz ondört hastanın (%59,8 erkek, n=367) 151 tanesi diyabet hastası (%24,5) idi. Diyabetli hastalar diyabeti olmayan hastalardan daha uzun süre hastanede yattı (12,1±10,3'e karşı 10,2±7,3 /gün p=0,037), diyabetlilerin yoğun bakım ünitesinde (YBÜ) yatış oranı (20,5% (n=31) ve 12,0% (n) =56), p=0,016, OR:1,8 (1,1-2,9)) ve ölüm oranları (%15,8 (n=24) ve %7,7 (n=36, p=0,007), OR:2,1(1,2-3,8)) daha yüksekti. Metformin, bazal insülin veya bolus insülin kullanan hastaların YBÜ’e yatışı açısından kullanmayanlara göre fark yoktu (sırasıyla p=0,32, p=0,22 ve p=0,64). Sodyum-glukoz kotransporter-2 tedavisi alan hiçbir hasta YBÜ'de tedavi edilmedi. Diyabet hastalarının ölüm oranı, aldıkları tedavi yöntemlerine göre hastalar arasında farklılık göstermedi. Sonuç: Diyabetli hastalar diyabetik olmayan hastalara göre daha kötü sonuçlara sahipti ve bizim bulgularımıza göre hiçbir antidiyabetik ilacın yararlı veya zararlı etkisi yoktu.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
0
0
0
  • 1. Ji Y, Ma Z, Peppelenbosch MP, Pan Q. Potential association between COVID-19 mortality and health-care resource availability. Lancet Glob Health. 2020;8(4):e480.
  • 2. Imam Z, Odish F, Gill I, O'Connor D, Armstrong J, Vanood A, Ibironke O, Hanna A, Ranski A, Halalau A. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. J Intern Med. 2020;288(4):469-476.
  • 3. Poblador-Plou B, Carmona-Pírez J, Ioakeim-Skoufa I, PoncelFalcó A, Bliek-Bueno K, Cano-Del Pozo M, Gimeno-Feliú LA, González-Rubio F, Aza-Pascual-Salcedo M, Bandrés-Liso AC, Díez-Manglano J, Marta-Moreno J, Mucherino S, GimenoMiguel A, Prados-Torres A, EpiChron Group. Baseline Chronic Comorbidity and Mortality in Laboratory-Confirmed COVID-19 Cases: Results from the PRECOVID Study in Spain. Int J Environ Res Public Health. 2020;17(14):5171.
  • 4. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054-1062.
  • 5. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, Qin R, Wang H, Shen Y, Du K, Zhao L, Fan H, Luo S, Hu D. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020:e3319.
  • 6. Guo L, Shi Z, Zhang Y, Wang C, Do Vale Moreira NC, Zuo H, Akhtar H. Comorbid diabetes and the risk of disease severity or death among 8807 COVID-19 patients in China: A metaanalysis. Diabetes Res Clin Pract. 2020;166:108346.
  • 7. Cheng X, Liu YM, Li H, Zhang X, Lei F, Qin j, Chen Z, Deng K, Lin L, Chen M, Song X, Xia M, Huang X, Liu W, Yuan Y, Wei X, She ZG, Ji YX, Li H. Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020;32(4):537-547.e3.
  • 8. Sharma S, Ray A, Sadasivam B. Metformin in COVID-19: A possible role beyond diabetes. Diabetes Res Clin Pract. 2020;164:108183.
  • 9. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Assem J,Satlin MJ, Campion TR, Nahid M, Ringel JB, Hoffman KL, Alshak MN, Li HA, Wehmeyer GT, Rajan MR, Evgeniya HN, Horn EM, Martinez FJ, Gulick RM, Safford MM. Clinical Characteristics of Covid-19 in New York City. N Engl J Med. 2020;382(24):2372-2374.
  • 10. Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth r, Klonof DC. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States. J Diabetes Sci Technol. 2020;14(4):813-821.
  • 11. Ciardullo S, Zerbini F, Perra S, Muraca E, Cannistraci R, Lauriola M, Grosso P, Lattuada G, Ippoliti G, Mortara A, Manzoni G, Perseghin G. Impact of diabetes on COVID19-related in-hospital mortality: A retrospective study from Northern Italy. J Endocrinol Invest. 2021;44(4):843-850.
  • 12. Mantovani A, Byrne CD, Zheng MH, Targher G. Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies. Nutr Metab Cardiovasc Dis. 2020;30(8):1236-1248.
  • 13. Holman N, Knighton P, Kar P, O’Keefe J, Curley M, Weaver A, Barron E, Bakhai C, Khunti K, Wareham NJ, Sattar N, Young B, Valabhji J. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: A population-based cohort study. Lancet Diabetes Endocrinol. 2020;8(10):823-833.
  • 14. Chen Y, Yang D, Cheng B, Chen J, Peng A, Yang C, Liu C, Xiong M, Deng A, Zhang Y, Zheng L, Huang K. Clinical Characteristics and Outcomes of Patients with Diabetes and COVID-19 in Association with Glucose-Lowering Medication. Diabetes Care. 2020;43(7):1399-1407.
  • 15. Dalan R, Ang LW, Tan WYT, Fong S-W, Tay WC, Chan YH, Renia L, Lisa FP, Lye DC, Chew DEK, Young BE. The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: An observational study. Eur Heart J Cardiovasc Pharmacother. 2021;7(3):e48-e51.
  • 16. Yu B, Li C, Sun Y, Wang DW. Insulin Treatment Is Associated with Increased Mortality in Patients with COVID-19 and Type 2 Diabetes. Cell Metab. 2021;33(1):65-77.e2.
  • 17. Riahi S, Sombra LRS, Lo KB, Chacko SR, Neto AGM, Azmaiparashvili Z, Patarroyo AG, Rangaswami j, Anastasopoulou C. Insulin Use, Diabetes Control, and Outcomes in Patients with COVID-19. Endocr Res. 2021;46(2):45-50.
  • 18. Solerte SB, Di Sabatino A, Galli M, Fiorina P. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19. Acta Diabetol. 2020;57(7):779-783.
  • 19. Strollo R, Maddaloni E, Dauriz M, Pedone C, Buzzetti R, Pozzilli P. Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths. Diabetes Res Clin Pract. 2021;171:108444.
APA Cakmak R, Telci Caklili O, Ok A, Mutlu Ü, Sarıbeyliler G, Seferova Nasifova V, Medetalibeyoglu A, Senkal N, Catma Y, Kose M (2021). COVID-19 and Diabetes Mellitus: Are there any Differences in Outcomes with Anti-Diabetic Drugs?. , 279 - 284. 10.25048/tudod.959022
Chicago Cakmak Ramazan,Telci Caklili Ozge,Ok Ayşe Merve,Mutlu Ümmü,Sarıbeyliler Göktuğ,Seferova Nasifova Vefa,Medetalibeyoglu Alpay,Senkal Naci,Catma Yunus,Kose Murat COVID-19 and Diabetes Mellitus: Are there any Differences in Outcomes with Anti-Diabetic Drugs?. (2021): 279 - 284. 10.25048/tudod.959022
MLA Cakmak Ramazan,Telci Caklili Ozge,Ok Ayşe Merve,Mutlu Ümmü,Sarıbeyliler Göktuğ,Seferova Nasifova Vefa,Medetalibeyoglu Alpay,Senkal Naci,Catma Yunus,Kose Murat COVID-19 and Diabetes Mellitus: Are there any Differences in Outcomes with Anti-Diabetic Drugs?. , 2021, ss.279 - 284. 10.25048/tudod.959022
AMA Cakmak R,Telci Caklili O,Ok A,Mutlu Ü,Sarıbeyliler G,Seferova Nasifova V,Medetalibeyoglu A,Senkal N,Catma Y,Kose M COVID-19 and Diabetes Mellitus: Are there any Differences in Outcomes with Anti-Diabetic Drugs?. . 2021; 279 - 284. 10.25048/tudod.959022
Vancouver Cakmak R,Telci Caklili O,Ok A,Mutlu Ü,Sarıbeyliler G,Seferova Nasifova V,Medetalibeyoglu A,Senkal N,Catma Y,Kose M COVID-19 and Diabetes Mellitus: Are there any Differences in Outcomes with Anti-Diabetic Drugs?. . 2021; 279 - 284. 10.25048/tudod.959022
IEEE Cakmak R,Telci Caklili O,Ok A,Mutlu Ü,Sarıbeyliler G,Seferova Nasifova V,Medetalibeyoglu A,Senkal N,Catma Y,Kose M "COVID-19 and Diabetes Mellitus: Are there any Differences in Outcomes with Anti-Diabetic Drugs?." , ss.279 - 284, 2021. 10.25048/tudod.959022
ISNAD Cakmak, Ramazan vd. "COVID-19 and Diabetes Mellitus: Are there any Differences in Outcomes with Anti-Diabetic Drugs?". (2021), 279-284. https://doi.org/10.25048/tudod.959022
APA Cakmak R, Telci Caklili O, Ok A, Mutlu Ü, Sarıbeyliler G, Seferova Nasifova V, Medetalibeyoglu A, Senkal N, Catma Y, Kose M (2021). COVID-19 and Diabetes Mellitus: Are there any Differences in Outcomes with Anti-Diabetic Drugs?. Türkiye Diyabet ve Obezite Dergisi , 5(3), 279 - 284. 10.25048/tudod.959022
Chicago Cakmak Ramazan,Telci Caklili Ozge,Ok Ayşe Merve,Mutlu Ümmü,Sarıbeyliler Göktuğ,Seferova Nasifova Vefa,Medetalibeyoglu Alpay,Senkal Naci,Catma Yunus,Kose Murat COVID-19 and Diabetes Mellitus: Are there any Differences in Outcomes with Anti-Diabetic Drugs?. Türkiye Diyabet ve Obezite Dergisi 5, no.3 (2021): 279 - 284. 10.25048/tudod.959022
MLA Cakmak Ramazan,Telci Caklili Ozge,Ok Ayşe Merve,Mutlu Ümmü,Sarıbeyliler Göktuğ,Seferova Nasifova Vefa,Medetalibeyoglu Alpay,Senkal Naci,Catma Yunus,Kose Murat COVID-19 and Diabetes Mellitus: Are there any Differences in Outcomes with Anti-Diabetic Drugs?. Türkiye Diyabet ve Obezite Dergisi , vol.5, no.3, 2021, ss.279 - 284. 10.25048/tudod.959022
AMA Cakmak R,Telci Caklili O,Ok A,Mutlu Ü,Sarıbeyliler G,Seferova Nasifova V,Medetalibeyoglu A,Senkal N,Catma Y,Kose M COVID-19 and Diabetes Mellitus: Are there any Differences in Outcomes with Anti-Diabetic Drugs?. Türkiye Diyabet ve Obezite Dergisi . 2021; 5(3): 279 - 284. 10.25048/tudod.959022
Vancouver Cakmak R,Telci Caklili O,Ok A,Mutlu Ü,Sarıbeyliler G,Seferova Nasifova V,Medetalibeyoglu A,Senkal N,Catma Y,Kose M COVID-19 and Diabetes Mellitus: Are there any Differences in Outcomes with Anti-Diabetic Drugs?. Türkiye Diyabet ve Obezite Dergisi . 2021; 5(3): 279 - 284. 10.25048/tudod.959022
IEEE Cakmak R,Telci Caklili O,Ok A,Mutlu Ü,Sarıbeyliler G,Seferova Nasifova V,Medetalibeyoglu A,Senkal N,Catma Y,Kose M "COVID-19 and Diabetes Mellitus: Are there any Differences in Outcomes with Anti-Diabetic Drugs?." Türkiye Diyabet ve Obezite Dergisi , 5, ss.279 - 284, 2021. 10.25048/tudod.959022
ISNAD Cakmak, Ramazan vd. "COVID-19 and Diabetes Mellitus: Are there any Differences in Outcomes with Anti-Diabetic Drugs?". Türkiye Diyabet ve Obezite Dergisi 5/3 (2021), 279-284. https://doi.org/10.25048/tudod.959022